Aligos Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $18.3M | $37.0M | $135.7M | $81.3M | $186.8M | $220.4M | $69.6M | $24.5M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $82.9M | $62.1M | $141.1M | $133.5M | $204.4M | $250.0M | $120.2M | — |
| Property, Plant & Equipment | $1.9M | $2.4M | $3.3M | $4.8M | $6.2M | $8.0M | $8.5M | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M | $265.3M | $146.5M | — |
| Liabilities | ||||||||
| Accounts Payable | $4.0M | $2.6M | $2.5M | $4.7M | $3.0M | $3.3M | $3.8M | — |
| Total Current Liabilities | $21.2M | $21.7M | $23.9M | $33.1M | $39.0M | $30.3M | $13.8M | — |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M | $45.3M | $29.3M | — |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-642.2M | $-618.0M | $-486.8M | $-399.1M | $-303.1M | $-174.7M | $-66.2M | — |
| Total Stockholders' Equity | $53.5M | $-29.0M | $92.1M | $103.9M | $184.7M | $220.0M | $-64.9M | $-13.7M |